Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $34
Portfolio Pulse from jenniferd'souza@benzinga.com
Barclays analyst Peter Lawson maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $31 to $34.
July 26, 2023 | 9:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Syndax Pharmaceuticals and raises the price target from $31 to $34, which could positively impact the stock in the short term.
The raised price target by Barclays indicates a positive outlook for Syndax Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100